Study of an investigational drug for faster recovery after heart surgery
Part of Heart & circulation clinical trials.
This trial tests a drug called EA-230 that may help people recover faster after heart bypass surgery. If you are having planned bypass surgery, this drug might shorten your hospital stay.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You are scheduled to have heart bypass surgery with at least 3 grafts, and the surgery is planned, not an emergency.
- You have not needed major heart support like a balloon pump, LVAD, or breathing tube in the past week.
- You do not have a serious infection, sepsis, or a weakened immune system.
- You do not have severe kidney or liver disease.
- If you are a woman who can have children, you must not be pregnant and must use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a gene therapy given during heart bypass surgery to help grow new blood vessels in the heart. It aims to improve blood flow to areas that bypass surgery alone can't fully fix.
This trial compares two types of heart bypass surgery for people with blockages in three main heart arteries. It tests a hybrid approach that combines a small incision bypass with a stent, versus a standard off-pump bypass. This may mean less recovery time for some patients.
This trial compares a simple leg-raising technique to a medicine (noradrenaline) to help keep blood pressure stable during heart bypass surgery. It may help you avoid stronger drugs and have a smoother recovery.
This trial tests a new artificial blood vessel for heart bypass surgery. If you need a bypass and meet the health requirements, you may be able to receive this experimental graft.
This study looks at a treatment that affects signals between heart cells in people with severe coronary artery disease who are scheduled for bypass surgery. The goal is to see if changing these heart-cell signals can improve heart outcomes around the time of surgery.
This study tests an experimental drug (ADR-002K) for people with heart failure caused by blocked arteries who are about to have bypass surgery. The goal is to see if it helps the heart recover better after surgery.
Hear when a new Coronary Artery Bypass Graft Surgery (CABG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.